Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
Clinical trial NCT04394624 · TERMINATED
Trial details
- NCT number
- NCT04394624
- Sponsor
- Sanofi
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-31
- Primary completion
- 2023-03-06
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.